Obesity market news — October 7, 2026
Novo Nordisk's liver-fat result is the kind of number that deserves its own paragraph of context, and the company supplied most of it. At EASD 2026 on October 1 Novo reported that among participants with excess liver fat, mean liver fat fell from 8.8 percent at baseline to 3.1 percent at week 72 on semaglutide, and that 23 of the 26 who entered above the 5 percent threshold finished below it. That is the 9-out-of-10 headline. Four things sit underneath it. The analysis is post hoc and exploratory, and Novo says so: liver fat was not a pre-specified primary or secondary endpoint of the parent trials. Liver fat was measured by MRI-PDFF in 55 participants, out of 1,919 adults in the pooled STEP UP and STEP UP T2D analysis. The 23-of-26 figure is therefore a subgroup of a subgroup. And the release does not give a placebo comparison for the liver-fat outcome, which matters because weight loss alone reduces liver fat. None of this makes the result uninteresting. A molecule already prescribed to millions showing this in the liver is a credible path to a second large indication, and Novo is pursuing that separately. It does mean the honest sentence is narrower than the headline: in a small, exploratory subgroup, liver fat normalised in most people who had it, in a trial that was not designed to ask.
The legal layer under this market has grown large enough to be a sector fact, and it is poorly covered because the search results belong to law firms advertising for clients. The numbers, as reported by litigation trackers citing the federal dockets in early October: roughly 4,025 personal-injury actions pending in MDL 3094, the gastroparesis and gastrointestinal-injury multidistrict litigation in the Eastern District of Pennsylvania, and roughly 247 in MDL 3163, which concerns NAION and vision loss. No trial and no settlement has occurred in either; the first bellwether trial is expected late 2026 or in 2027. We flag two things about our own sourcing. These counts come from trackers, not from a document the courts published, and we could not retrieve a primary docket statistic; treat the magnitude as reliable and the exact figure as approximate. And the location matters: the federal gastrointestinal MDL sits in Pennsylvania, not New Jersey, which is where a separate state-court mass tort is consolidated. For an investor the useful frame is neither the alarm nor the dismissal. Four thousand filings before any trial tells you about plaintiff-firm advertising volume as much as about injury rates. What will tell you something is the first bellwether verdict, because that is when a number gets attached to the risk. Until then this is a dated calendar item, not a valuation input.
Novo Nordisk (NVO): What changed: Novo Nordisk reported liver-fat data for semaglutide at the EASD annual meeting at 06:45 Eastern time on October 1. Against what: liver fat was not an endpoint of the parent trials, so this is new evidence on an old dataset rather than a new trial. In a pooled post hoc exploratory analysis of STEP UP and STEP UP T2D, covering 1,919 adults of whom 1,312 received semaglutide 7.2 mg, 304 received 2.4 mg and 303 received placebo, liver fat was measured by MRI-PDFF in 55 participants with excess liver fat. Mean liver fat on semaglutide fell from 8.8 percent at baseline to 3.1 percent at week 72, and 23 of the 26 participants who began above the 5 percent threshold, or 88.5 percent, finished below it. Novo states that the analysis was post hoc and exploratory and was not a pre-specified primary or secondary endpoint. The release does not report a placebo comparison for the liver-fat outcome. Source: the company release of October 1.
Viking Therapeutics (VKTX): What changed, and what did not. Viking began Part 2 of its ongoing VK2735 maintenance study today, in roughly 195 adults with obesity. After a 21-week subcutaneous induction, participants move to daily oral tablets, weekly oral tablets, subcutaneous every other week, monthly subcutaneous, or placebo. What did not change: this is not the oral VK2735 Phase 3 programme, which Viking guided to the fourth quarter of 2026 and has not announced. The distinction matters because the headline reads as the Phase 3 start. Part 2 extends the dose-ranging maintenance work whose Part 1 reported on September 22; the Phase 3 would be a separate registrational efficacy trial, and VANQUISH-1 and VANQUISH-2 are separate again, testing fixed weekly subcutaneous dosing over 78 weeks. We keep the oral Phase 3 on the watchlist as open and inside its window.
US federal courts (MDL 3094, MDL 3163): Scale of the GLP-1 product-liability litigation, as reported by litigation trackers citing the federal dockets in early October: approximately 4,025 personal-injury actions pending in MDL 3094 in the Eastern District of Pennsylvania, covering gastroparesis, ileus and bowel obstruction, and approximately 247 in MDL 3163, covering NAION and vision loss. No trial and no settlement has occurred in either, and the cases remain in pretrial discovery, with a first bellwether expected late 2026 or 2027. Two qualifications we owe the reader: these counts come from trackers rather than a court-published statistic, so the magnitude is reliable and the precise figure approximate; and the federal gastrointestinal MDL sits in Pennsylvania, not New Jersey, where a separate state mass tort is consolidated.
US Department of Veterans Affairs, US Department of Defense: A dating correction, because this circulated this week as a new guideline. The VA/DoD clinical practice guideline for the management of adult overweight and obesity, which recommends semaglutide or tirzepatide alongside comprehensive lifestyle intervention for adults with a body mass index of 30 or above, or 27 or above with an obesity-associated condition, was published on November 5, 2025 and reviewed on September 8, 2026. The trade coverage this week is coverage of a guideline that is nearly a year old. The substance holds and the institutional endorsement is real; the novelty is not. We note it because a guideline date is exactly the kind of fact that gets lost between the source and the headline.
Viking Therapeutics (VKTX), Zealand Pharma (ZEAL), Roche: The watchlist at the start of the fourth quarter. Open and inside its window: Viking's oral VK2735 Phase 3, guided to the fourth quarter of 2026, with the quarter one week old; today's Part 2 start is a different study. Open and inside its window: the Phase 2 ZYNERGY combination trial of petrelintide with Roche's enicepatide, guided to the second half of 2026, with until December. Closed on the record this quarter: Viking's maintenance readout on September 22 and Zealand's ZUPREME Phase 3 start on September 22, both within their guided windows. Running total since we began counting on August 31: five tracked commitments, two closed on the record, two open and current, none quietly rolled forward, and one we initially recorded in error and corrected on September 14.
Eli Lilly (LLY), Amgen (AMGN), Altimmune (ALT), Structure Therapeutics (GPCR): We checked company releases for the other followed companies covering September 29 to October 7 and found no dated corporate change at Eli Lilly, Amgen, Altimmune or Structure Therapeutics in that window. That is a checked absence, not an assumption. Disclosure: the author holds shares in Novo Nordisk and Eli Lilly, both named in this edition; the full statement is on the About page.